Gilead Sciences, Inc’s recently made public that its Chairman & CEO O’Day Daniel Patrick unloaded Company’s shares for reported $1.19 million on Oct 28 ’25. In the deal valued at $119.39 per share,10,000 shares were sold. As a result of this transaction, O’Day Daniel Patrick now holds 581,203 shares worth roughly $71.49 million.
Then, DANIEL ODAY bought 10,000 shares, generating $1,193,926 in total proceeds.
Before that, Dickinson Andrew D sold 2,500 shares. Gilead Sciences, Inc shares valued at $295,200 were divested by the Chief Financial Officer at a price of $118.08 per share. As a result of the transaction, Dickinson Andrew D now holds 157,055 shares, worth roughly $19.32 million.
Daiwa Securities upgraded its Gilead Sciences, Inc [GILD] rating to an Outperform from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who increased its forecast for the stock in early August from “a Hold” to “a Buy”. Needham also remained covering GILD and has increased its forecast on July 25, 2025 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of GILD
On Tuesday, Gilead Sciences, Inc [NASDAQ:GILD] saw its stock jump 0.78% to $123.0. Over the last five days, the stock has gained 4.34%. Gilead Sciences, Inc shares have risen nearly 38.48% since the year began. Nevertheless, the stocks have risen 33.16% over the past one year. While a 52-week high of $124.61 was reached on 10/21/25, a 52-week low of $86.08 was recorded on 01/10/25.
Levels Of Support And Resistance For GILD Stock
The 24-hour chart illustrates a support level at 120.30, which if violated will result in even more drops to 117.60. On the upside, there is a resistance level at 124.64. A further resistance level may holdings at 126.27.
How much short interest is there in Gilead Sciences, Inc?
A steep rise in short interest was recorded in Gilead Sciences, Inc stocks on 2025-10-15, dropping by -2.44 million shares to a total of 15.8 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 18.25 million shares. There was a decline of -15.47%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 04, 2025 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $132.
